Results 51 to 60 of about 1,820,370 (346)

Recombinant expression systems: the obstacle to helminth vaccines? [PDF]

, 2007
A
Claerebout, Edwin, De Maere, Veerle, Geldhof, Peter, Vercruysse, Jozef   +3 more
core   +2 more sources

Bacterial surface proteins and vaccines [PDF]

F1000 Biology Reports, 2010
Surface-associated proteins play a key role in bacterial physiology and pathogenesis and are the major targets for vaccine development. Recent advances in defining the proteins associated with, and protruding out of, bacterial cells to a high level of accuracy are substantially contributing to accelerating the process of vaccine target identification ...
openaire   +3 more sources

Determination of Endotoxicity in Bacterial Vaccines [PDF]

Applied Microbiology, 1973
Endotoxicity of bacterial vaccines was quantitated in mice by using actinomycin D as potentiating agent. The results were compared with those obtained by the mouse weight gain test. The lethality of Escherichia coli lipopolysaccharide was increased 2,140 times when 12.5 μg of actinomycin D was used.
K. H. Wong, K. H. Wong, John C. Feeley, John C. Feeley, Y. K. Chan, Y. K. Chan, C. E. Miller, C. E. Miller   +7 more
openaire   +3 more sources

Dual effect of Thymosin α 1 on human monocyte-derived dendritic cellin vitrostimulated with viral and bacterial toll-like receptor agonists [PDF]

, 2015
OBJECTIVES: Thymosin α 1 (Tα1) recently gained interest as immune adjuvant for vaccines because of its ability to modulate the T-cell/dendritic cell (DC) axis and to improve antibody production.
Coccia, Eliana Marina, Cruciani, Melania, Etna, Marilena Paola, Garaci, Enrico, Giacomini, Elena, Pardini, Manuela, Rizzo, Fabiana, SCAGNOLARI, CAROLINA, Severa, Martina   +8 more
core   +1 more source

PECULIARITIES OF CULTIVATION OF HAEMOPHILUS INFLUENZAE TYPE B STRAINS - PRODUCERS OF POLYRIBOSYLRIBITOL PHOSPHATE - THE MAIN COMPONENT OF POLYSACCHARIDE VACCINES

Фармация и фармакология (Пятигорск), 2017
One of the up-to-date challenges of modern immunobiotechnology is the development and introduction of an effective vaccine against the infection caused by the bacterium Haemophilus influenza, type b (Hib). The main active substance of the vaccine against
E. L. Salimova, A. D. Konon, S. V. Petrovskii, V. P. Truhin, I. V. Krasilnikov   +4 more
doaj   +1 more source

Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States

BMC Infectious Diseases, 2023
Background Invasive extraintestinal pathogenic Escherichia coli disease (IED) can lead to severe outcomes, particularly among older adults. However, the clinical burden of IED in the U.S. has not been well characterized.
Luis Hernandez-Pastor, Jeroen Geurtsen, Bryan Baugh, Antoine C. El Khoury, Nnanya Kalu, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Martin Cloutier, Michal Sarnecki, Elie Saade   +9 more
doaj   +1 more source

DNA vaccines for bacterial infections

Immunology & Cell Biology, 1997
DNA vaccines are an exciting development in vaccine technology which may have a special role in preventing viral infections and as ‘theracines’ for cancer. Their use in preventing bacterial infections has, by comparison, been less well documented.
Strugnell, RA, Drew, D, Mercieca, J, Dinatale, S, Firez, N, Dunstan, SJ, Simmons, CP, Vadolas, J   +7 more
openaire   +5 more sources

Membrane vesicles derived from Bordetella bronchiseptica: Active constituent of a new vaccine against infections caused by this pathogen [PDF]

, 2018
Bordetella bronchiseptica, a Gram-negative bacterium, causes chronic respiratory tract infections in a wide variety of mammalian hosts, including humans (albeit rarely).
Bartel, Erika Belén, Bottero, Daniela, Gaillard, María Emilia, Hozbor, Daniela Flavia, Vercellini, María Clara, Zurita, Maria Eugenia   +5 more
core   +2 more sources

IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE

International Journal of Infectious Diseases, 2023
Intro: The safety, reactogenicity, and immunogenicity of VAC52416 (ExPEC10V), a vaccine candidate to prevent invasive Escherichia coli disease, was assessed in a phase 1/2a study (NCT03819049). Results from Cohort 1 have been presented. Here, we describe
C. Fierro, M. Sarnecki, J. Doua, B. Spiessens, O. Go, T. Davies, G. van den Dobbelsteen, J. Poolman, D. Abbanat, W. Haazen   +9 more
doaj  

Toward an Improved Meningococcal Serogroup B Assay

mBio, 2018
Because of diverse sequences and differential expression of surface structures on individual invasive Neisseria meningitidis serogroup B (MenB) strains, predicting the efficacy of MenB vaccines using traditional human serum bactericidal assays (hSBA) is ...
Jan Poolman
doaj   +1 more source